KZR Kezar Life Sciences6.17+2.00 (+48.0%)
After Hours Gainer
KZR Kezar Life Sciences4.17-0.13-3.0%
After Hours:6.06+1.89 (+45.3%)
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
Business WireThu, 16-Oct 4:05 PM
After Hours:6.05+1.88 (+45.1%)
Premarket Decliner
KZR Kezar Life Sciences6.16+0.27+4.6%
Premarket:5.80-0.36 (-5.8%)
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Business WireTue, 25-Mar 7:30 AM
KZR Kezar Life Sciences3.39-0.16 (-4.5%)
KZR Kezar Life Sciences3.56+0.21 (+6.3%)